Liminatus Pharma, Inc. (LIMN) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001971387 · SEC filings checked Oct 19, 2026
Next report
Not yet known
Fewer than three past results filings to estimate from.
Last close
$3.12
Polygon.io daily close, Oct 21, 2026. End of day, not live.
Trailing diluted EPS
$-0.47
Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 14, 2026 | — | $-1.4M | $-0.03 | Filing |
| Mar 31, 2026 | May 15, 2026 | — | $-1.1M | $-0.03 | Filing |
| Dec 31, 2025 | Mar 31, 2026 | — | $-8.2M | $-0.34 | Filing |
| Sep 30, 2025 | Nov 14, 2025 | — | $-1.8M | $-0.07 | Filing |
| Jun 30, 2025 | Oct 6, 2025 | — | $113,287 | $0.00 | Filing |
| Mar 31, 2025 | Jun 2, 2025 | — | $-327,526 | $-0.02 | Filing |
| Dec 31, 2024 | — | — | $-229,752 | $2.35 | — |
| Sep 30, 2024 | — | — | $-601,372 | $-0.03 | — |
What would Liminatus Pharma, Inc. have to report for its valuation to change?
Trailing earnings are negative, so a price-to-earnings reverse model does not apply. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.